{
    "clinical_study": {
        "@rank": "50318", 
        "arm_group": [
            {
                "arm_group_label": "Arm A (RFA)", 
                "arm_group_type": "Experimental", 
                "description": "RFA electrode: Cool-tip RF ablation system (Covidien plc, 20 Lower Hatch Street Dublin 2, Ireland) and Well-Point RF Electrode (STARmed, Koea)\nperformed using either the manufacturer's standard algorithm or an interactive algorithm, with the latter being used when the impedance did not begin to increase at the midinterval of the standard algorithm"
            }, 
            {
                "arm_group_label": "Arm B (Proton)", 
                "arm_group_type": "Experimental", 
                "description": "66 GyE /10 fx, 6.6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30<40%,and/or RLV30<30%)"
            }
        ], 
        "brief_summary": {
            "textblock": "This phase 3 study is to evaluate the effectiveness of the comparison between radiofrequency\n      ablation and hypofractionated proton beam radiation."
        }, 
        "brief_title": "Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Recurrent Small Hepatocellular Carcinoma", 
            "Residual Small Hepatocellular Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "The sample size for this study was based on a non-inferiority design. Primary objective:\n      estimate local progression-free survival (LPFS) rate in two treatments Primary endpoint:\n      2-year LPFS rate Expected 2-year LPFS rate in the RFA: 85% Accural time and follow up time:\n      24 months and 24 months, respectively. Precision for 2-year LPFS rate estimation: Allowing a\n      difference of 15% as the non-inferiority margin, with a power of 80% and a type I error\n      level of 5%, evaluable 68 patients are required.\n\n      Considering 5% of follow-up loss, we need 72 patients in each arm, so a total of 144\n      patients will be enrolled."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HCC diagnosed as (i) the presence of risk factors including hepatitis B or C virus\n             and liver cirrhosis, a serum a-fetoprotein (AFP) level greater than 200 IU/ml and a\n             radiologically compatible feature with HCC in one or more CT/MRI/angiograms, or (ii)\n             the presence of risk factors including hepatitis B or C virus and liver cirrhosis, a\n             serum a-fetoprotein (AFP) level less than 200 IU/ml, and a radiologically compatible\n             feature with HCC in two or more CT/MRI/angiograms or (iii) histological confirmation\n\n          -  HCC patients who had recurrent or residual tumor after other treatments\n\n          -  without evidence of extrahepatic metastasis\n\n          -  the largest diameter of tumor should be less than 3cm, and the number of tumor \u22642\n\n          -  no previous treatment to target tumors by other forms of RT\n\n          -  liver function of Child-Pugh class A or B7 (Child-Pugh score of \u22647)\n\n          -  Age of \u226518 years\n\n          -  performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) score\n\n          -  WBC count \u2265 2,000/mm3; hemoglobin level \u2265 7.5 g/dL; platelet count \u2265 50,000/mm3; and\n             adequate hepatic function (total bilirubin \u2264 3.0 mg/dL; AST and ALT < 5.0\u00d7 upper\n             limit of normal; no ascites)\n\n          -  no serious comorbidities other than liver cirrhosis\n\n          -  written informed consent\n\n        Exclusion Criteria:\n\n          -  evidence of extrahepatic metastasis\n\n          -  age < 18 years\n\n          -  liver function of Child-Pugh class B8-9 and C (Child-Pugh score of >7) or\n             uncontrolled cases of active chronic hepatitis B\n\n          -  previous history of other forms of RT adjacent to target tumors\n\n          -  poor performance status of 3 to 4 on the Eastern Cooperative Oncology Group (ECOG)\n             score\n\n          -  pregnant or breast feeding status\n\n          -  previous history uncontrolled other malignancies within 2 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963429", 
            "org_study_id": "NCCCTS 13-695"
        }, 
        "intervention": {
            "arm_group_label": [
                "Arm A (RFA)", 
                "Arm B (Proton)"
            ], 
            "intervention_name": "Proton beam therapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hepatocellular", 
            "Proton", 
            "RFA"
        ], 
        "lastchanged_date": "October 15, 2013", 
        "location": {
            "contact": {
                "email": "jwpark1@ncc.re.kr", 
                "last_name": "Joong Won Park, Ph.D", 
                "phone": "+82-31-920-1605"
            }, 
            "contact_backup": {
                "email": "k2onco@ncc.re.kr", 
                "last_name": "Tae Hyun Kim, Ph.D", 
                "phone": "+82-31-920-1725"
            }, 
            "facility": {
                "address": {
                    "city": "Goyang-si", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi-do", 
                    "zip": "410-769"
                }, 
                "name": "National Cancer Center, Korea"
            }, 
            "investigator": [
                {
                    "last_name": "Tae Hyun Kim, Ph.D", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Young Hwan Koh, Ph.D", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ju Hee Lee, Ph.D", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Chang Min Kim, Ph.D", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bo Hyun Kim, Ph.D", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Min Ju Kim, Ph.D", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Bung Ho Nam, Ph.D", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase III Study of the Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation in Patients With Recurrent/Residual Small Hepatocellular Carcinoma (APROH Study)", 
        "other_outcome": {
            "description": "Overall survival(OS) was defined as the interval from the date of randomization to date of detection study closed", 
            "measure": "overall survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "up to 2 years until study closed"
        }, 
        "overall_contact": {
            "email": "jwpark1@ncc.re.kr", 
            "last_name": "Joong Won Park, Ph.D", 
            "phone": "+82-31-920-1605"
        }, 
        "overall_contact_backup": {
            "email": "k2onco@ncc.re.kr", 
            "last_name": "Tae Hyun Kim, Ph.D", 
            "phone": "+82-31-920-1725"
        }, 
        "overall_official": {
            "affiliation": "National Cancer Center, Korea", 
            "last_name": "Joong Won Park, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the local progression-free survival (1cm from ablation cavity or 1.5cm form gross tumor) for 2 years", 
            "measure": "local progression-free survival(LPES)", 
            "safety_issue": "No", 
            "time_frame": "up to 2 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963429"
        }, 
        "responsible_party": {
            "investigator_affiliation": "National Cancer Center, Korea", 
            "investigator_full_name": "Joong-Won Park", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Disease-free survival was defined as the interval from the date of randomization to date of detection study closed", 
            "measure": "disease-free survival (DFS)", 
            "safety_issue": "No", 
            "time_frame": "up to 2 years until study closed"
        }, 
        "source": "National Cancer Center, Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Center, Korea", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}